logo
Share SHARE
FONT-SIZE Plus   Neg

Amended: Ampio Pharma Says FDA Accepts IND For Diabetic Macular Edema Drug

Corrects Headline & 1st Para to Indicate FDA Accepts IND for Eye Drug

Ampio Pharmaceuticals, Inc. (AMPE) Tuesday said the FDA has accepted its IND for Optina, an oral drug used in the treatment of diabetic macular edema, or DME.

Optina had been given 505-b-2 status by FDA in July, 2012. Drugs designated under this pathway can be approved on a single trial.

DME is a devastating complication of diabetes and is manifested by local and systemic inflammation. Optina also has the potential to treat other systemic complications of diabetes such as nephropathy, said the company.

The planned multi-center trial, scheduled to begin in the first quarter, is designed to evaluate the safety and efficacy of oral Optina compared with placebo given over a period of 12 weeks in adult patients with DME.

Patients will be randomized to receive one of two doses of Optina per day or placebo. Interim analysis will occur after patients have completed 4 weeks of initial treatment.

Following the 12 week active treatment period, there will be a further 4 week washout period to determine regression of treatment effect.

The primary endpoint is improvement in visual acuity, defined by responder status, compared to placebo, while secondary endpoints include measurements of changes in VA and central macular thickness, tolerability etc.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple Inc. is working on a self-driving shuttle service to ferry employees within its sprawling campus, the New York Times reported. The move comes after the tech giant decided to abandon the idea of building an entire self-driving car by itself. Women who are between 25 and 34 years old are losing the race in the U.S. when it comes to pay equality with men, data from the Bureau of Labor Statistics showed. This is despite the rapid increase in participation of women in the labor force. Eric Daniels, the former chief executive of Lloyds Banking Group, is suing the bank for hundreds of thousands of pounds in disputed bonuses, The Times reported. He was at the top job when the lender was bailed out with 20 billion pounds of taxpayer money during the 2008 financial crisis.
comments powered by Disqus
Follow RTT